NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

4D Molecular Therapeutics, Inc. (FDMT) Stock Analysis

4D Molecular Therapeutics, Inc. (FDMT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

FDMT

$14.97

+$0.27 (+1.84%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FDMT with… →

FDMT Key Statistics

As of Sep 4, 2026
Trading
Open
$14.50
Previous Close
$14.70
Day's Range
14.33–15.00
52-Week Range
6.47–16.93
Volume
420.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.73
Valuation
Market Cap
$827.01M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.99
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.68
Financials (FY)
Revenue (FY)
$85.21M+230194.59%
Net Income (FY)
−$140.11M
Profit marginThe share of revenue left as profit after all costs and taxes.
−194.74%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
55.24M
1-Year Return
+126.48%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
954.88K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FDMT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+99.60%
2025+34.65%
2024−72.51%
2023−8.78%
2022+1.23%
2021−47.07%
2020 (partial year)+2.35%

As of September 4, 2026.

FDMT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$85.21M−$140.11M−164.4%
2024$37.00K−$160.87M−434778.4%
2023$20.72M−$100.84M−486.6%
2022$3.13M−$107.49M−3435.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$85.21M—−$159.55M−$140.11M−164.4%
2024$37.00K—−$187.84M−$160.87M−434778.4%
2023$20.72M—−$112.87M−$100.84M−486.6%
2022$3.13M—−$110.03M−$107.49M−3435.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FDMT Valuation vs Biotechnology Median

Median of 656 stocks
MetricFDMTBiotechnology medianvs median
P/S ratio8.9915.2641% below
Profit margin−194.74%0.00%194.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values 4D Molecular Therapeutics, Inc. (FDMT) at $827.01M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 196.

FDMT last closed at $14.97 on September 4, 2026. That is +$0.27 (+1.84%) against the previous close. The 52-week range on file runs from $6.47 to $16.93. The latest close sits 131.48% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $85.21M. That is +230,194.59% against the prior fiscal year, when revenue was $37.00K. The same year closed with a net loss of $140.11M. Profit margin runs at −194.74%. That is 194.7 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −2.68.

Across the 4 fiscal years on file, revenue moves from $3.13M in 2022 to $85.21M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 8.99 times revenue. On price-to-sales that is 41.11% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +126.48%. Across 5 years the annualized return works out at −14.19%. The reported beta is 2.73. Annualized volatility over the trailing 5 years is 92.64%.

Growth & Income

The record shows no dividend for FDMT.

So far in 2026 the price is +99.60%. The strongest complete calendar year on file is 2025 at +34.65%; the weakest is 2024 at −72.51%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

4D Molecular Therapeutics, Inc. (FDMT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
4D Molecular Therapeutics, Inc. FDMT $827.01M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. 4D Molecular Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Visit website →